Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sevelamer

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

- PMLiVE

FDA sets August review date for Teva’s movement disorder drug

Could be first approved treatment for tardive dyskinesia

Sanofi reception

Praluent can stay on market for now, says US court

Sanofi and Regeneron win appeal to suspended permanent injunction sought by Amgen

- PMLiVE

GSK’s Witty ends on a high, but warns 2017 looking ‘uncertain’

Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline

- PMLiVE

Amgen’s chronic kidney disease drug Parsabiv cleared in US

Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

- PMLiVE

Change at the top at Teva as Vigodman departs

CEO replaced ad interim by chairman Yitzhak Peterburg as search begins

- PMLiVE

Sanofi appoints general manager UK

Hugo Fry previously served as chief marketing officer at Sanofi Pasteur

Sanofi reception

Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Competition to Roche’s blockbuster RA therapy heats up as Canada is first to licence new drug

AstraZeneca AZ

AZ, FibroGen’s anaemia drug on course for first filing this year

Potential first-in-class blockbuster lines up to seek approval in China

- PMLiVE

Biogen’s corporate affairs SVP joins Sanofi

Kathleen Tregoning becomes executive vice president, external affairs

Actelion HQ Switzerland

Actelion reports late-stage trial failure as J&J talks continue

MAESTRO trial results disappointing but unlikely to lead to a breakdown in talks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links